国产午夜不卡Av免费,国产成人精品久久一区二区三区,亚洲国产精品久久久久秋霞1,日日摸日日踫夜夜爽无码

Dr. Yongkui Sun, previously a VP of Merck Sharp & Dohme (MSD) R&D (China), has 22 years tenure in 6 MSD departments. Dr. Sun possesses rich experiences in R&D, strategy, operations, and business development, and contributed to several drugs including Cordaptive^®, Taranabant ^®, and Januvia^®.

Honor and Awards include:

British Society of Chemical Engineers AstraZeneca Green Chemistry and Engineering Award (2005), US Presidential Green Chemistry Challenge Award (2005 and 2006), Thomas Edison Patent Award (2009), American Pharmaceutical Association Award (2009), elected as a member of the US National Academy of Engineering (2016)

Members of the United States National Academy of Engineering

PhD in Chemistry, California Institute of Technology

Extensive drug discovery and early development experience in large international and domestic pharmaceutical companies and CROs.
Chief Scientific Officer in IONOVA, leading the global development strategy and execution of IONOVA R&D pipeline.
Ph.D. in biochemistry, Baylor College of Medicine, Houston.

Dr. Zhaopie Zeng has nearly 30 years of experience in drug metabolism and pharmacokinetics.

Before joining Ionova, she was the head of Drug Metabolism Department of Sanofi U.S. and held key positions in Bayer, MSD and Boehringer in America.

Honor and Awards include:

Recipient of Sanofi Breakthrough Award, Merck Sharp & Dohme Excellence Award, etc.

Dr. Yi Zhu has 25 years of clinical R&D management and commercial management experience in the U.S.

Formerly served at the University of Pennsylvania School of Medicine, American College of Radiology, and Sanofi, conducted the development of clinical research program strategy and operational management.

She has led the clinical development of many global new drugs, radiological imaging markers, medical device INDs, NDAs, with extensive clinical development experience in oncology and central nervous system diseases. Dr. Zhu is also experienced in the entire drug-to-market process:  from translational medicine to FDA approval.

She co-founded a medical imaging CRO in the U.S. and successfully expanded the strategic partnership between pharmaceutical companies and medical imaging CROs.